openPR Logo
Press release

Investigation announced for Investors in Biohaven Ltd. (NYSE: BHVN) over potential Wrongdoing

An investigation on behalf of investors in Biohaven Ltd. (NYSE: BHVN) shares over potential wrongdoing at Biohaven Ltd.

An investigation on behalf of investors in Biohaven Ltd. (NYSE: BHVN) shares over potential wrongdoing at Biohaven Ltd.

An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Biohaven Ltd.

Investors who purchased shares of Biohaven Ltd. (NYSE: BHVN) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm concerns whether certain Biohaven Ltd. directors breached their fiduciary duties and caused damage to the company and its shareholders.

New Haven, CT based Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States.

On July 27, 2023, Biohaven Ltd. announced, among other items, that "[o]n its SCA program, the FDA informed Biohaven that it would not review the recently submitted NDA application for troriluzole given that the study's primary endpoint was not met and thus, would not permit a substantive review."

Shares of Biohaven Ltd. (NYSE: BHVN) declined from $25.84 per share on June 14, 2023, to as low as $17.10 per share on July 27, 2023.

Those who purchased shares of Biohaven Ltd. (NYSE: BHVN) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in Biohaven Ltd. (NYSE: BHVN) over potential Wrongdoing here

News-ID: 3531405 • Views:

More Releases from Shareholders Foundation, Inc.

Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potential Wrongdoing
Novo Nordisk A/S (NYSE: NVO) Long Term Investor Alert: Investigation of potentia …
An investigation on behalf of current long-term investors in shares of Novo Nordisk A/S (NYSE: NVO) concerning potential breaches of fiduciary duties by certain directors and officers was announced. Investors who are current long term investors in Novo Nordisk A/S (NYSE: NVO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for long term investors in
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ: FTNT)
Lawsuit filed for Investors who lost money with shares of Fortinet, Inc. (NASDAQ …
An investor, who purchased shares of Fortinet, Inc. (NASDAQ: FTNT), filed a lawsuit over alleged violations of Federal Securities Laws by Fortinet, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Fortinet, Inc. (NASDAQ: FTNT) have certain options and for certain investors are short and strict deadlines running. Deadline: November 21, 2025. NASDAQ: FTNT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on October 07, 2025
CTO Realty Growth, Inc. (NYSE: CTO) Investor Alert: Deadline in Lawsuit on Octob …
A deadline is coming up on October 07, 2025in the lawsuit filed for certain investors of CTO Realty Growth, Inc. (NYSE: CTO) over alleged securities laws violations by CTO Realty Growth, Inc. Investors who purchased shares of CTO Realty Growth, Inc. (NYSE: CTO) have certain options and there are strict and short deadlines running. Deadline: October 07, 2025. CTO Realty Growth, Inc. (NYSE: CTO) stockholders should contact the Shareholders Foundation at
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR)
Alert: Lawsuit filed for Investors who lost money with shares of Jasper Therapeu …
An investor, who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR), filed a lawsuit over alleged violations of Federal Securities Laws by Jasper Therapeutics, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Jasper Therapeutics, Inc. (NASDAQ: JSPR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 18, 2025. NASDAQ: JSPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for Biohaven

Obsessive Compulsive Disorder Market Dynamics Indicate Upward Trajectory Through …
The Key Obsessive Compulsive Disorder Companies in the market include - Biohaven Pharmaceuticals, Inc., AbbVie, AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, Ortho-McNeil Pharmaceutical, Forest Laboratories, Eli Lilly and Company, Janssen-Ortho Inc., Pfizer, and others. DelveInsight's "Obsessive Compulsive Disorder Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Obsessive Compulsive Disorder, historical and forecasted epidemiology as well as the Obsessive Compulsive Disorder market trends in the United States, EU4 (Germany,
Biohaven Ltd. (NYSE: BHVN) Long Term Investor Alert: Investigation of potential …
An investigation on behalf of current long-term investors in shares of Biohaven Ltd. (NYSE: BHVN) concerning potential breaches of fiduciary duties by certain directors and officers was announced. Investors who are current long term investors in Biohaven Ltd. (NYSE: BHVN) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE:
Obsessive Compulsive Disorder Market Growth Projections 2024-2034: DelveInsight …
The Key Obsessive Compulsive Disorder Companies in the market include - Biohaven Pharmaceuticals, Inc., AbbVie, AstraZeneca, MedtronicNeuro, Hoffmann-La Roche, Ortho-McNeil Pharmaceutical, Forest Laboratories, Eli Lilly and Company, Janssen-Ortho Inc., Pfizer, and others. DelveInsight's "Obsessive Compulsive Disorder Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Obsessive Compulsive Disorder, historical and forecasted epidemiology as well as the Obsessive Compulsive Disorder market trends in the United States, EU4 (Germany,
Obsessive Compulsive Disorder Market to Show Remarkable Growth Trends from 2024 …
DelveInsight's "Obsessive Compulsive Disorder Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Obsessive Compulsive Disorder, historical and forecasted epidemiology as well as the Obsessive Compulsive Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the OCD market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obsessive Compulsive Disorder Market Forecast [https://www.delveinsight.com/sample-request/obsessive-compulsive-disorder-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr] Some
Obsessive Compulsive Disorder Market Expected to Experience Major Growth by 2034 …
DelveInsight's "Obsessive Compulsive Disorder Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Obsessive Compulsive Disorder, historical and forecasted epidemiology as well as the Obsessive Compulsive Disorder market trends in the United States, EU4 (Germany, Spain, Italy, France, and United Kingdom) and Japan. To Know in detail about the OCD market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Obsessive Compulsive Disorder Market Forecast https://www.delveinsight.com/sample-request/obsessive-compulsive-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr Some
Spinocerebellar Ataxias Market Value Strategic Analysis | Biohaven Pharmaceutica …
According to HTF Market Intelligence, the Spinocerebellar Ataxias market to witness a CAGR of xx% during the forecast period (2024-2030). The Latest published a market study on Global Spinocerebellar Ataxias Market provides an overview of the current market dynamics in the Global Spinocerebellar Ataxias space, as well as what our survey respondents- all outsourcing decision-makers- predict the market will look like in 2030. The study breaks the market by revenue